Aponia Laboratories, Inc. is focused on developing innovative topical pain relief products that leverage ibuprofen as a key active ingredient. The company operates within the non-steroidal anti-inflammatory drugs (NSAIDs) segment of the arthritis pain market, which is valued at $24.2 billion. Aponia is committed to creating both prescription (Rx) and over-the-counter (OTC) formulations that are designed to be safe and effective. Their approach includes a unique molecular bifurcation of ibuprofen, which enhances the efficiency and safety of their products. The company has established a robust intellectual property strategy, securing patents for their transdermal compositions and methods of use, which underscores their commitment to innovation in pain management.

The research and development efforts at Aponia Laboratories are guided by a world-class team with a proven track record in successfully navigating the New Drug Application (NDA) process with the FDA. Their pipeline includes products that have completed formulation development and extensive non-clinical studies, and are currently undergoing comprehensive clinical trials. The leadership team, comprising experienced professionals like Kenneth Corroon and Robert Boolbol, brings a wealth of knowledge in healthcare and pain management, further positioning Aponia as a leader in the development of topical pain relief solutions.

United States

Aponia Laboratories, Inc. was founded by Robert Boolbol, M.D. and Kenneth Corroon in 2010 to develop and introduce a safe and over-the-counter pain mitigation products.

Aponia Laboratories

Company Details